Corcept Therapeutics Incorporated (NASDAQ: CORT) Stock Competitors & Peer Comparison
See CORT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CORT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CORT | $110.29 | -3.98% | 11.9B | 315.11 | $0.35 | N/A |
| RPRX | $58.41 | -0.88% | 25.9B | 11.13 | $5.25 | +1.59% |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| LQDA | $66.88 | -2.21% | 5.9B | 477.71 | $0.14 | N/A |
| KNSA | $77.24 | -2.63% | 5.9B | 85.82 | $0.90 | N/A |
| PBH | $44.97 | -3.23% | 2.1B | 10.17 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| LTGO | $22.55 | -5.77% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| HELP | $12.37 | -11.77% | 766.7M | -2.97 | -$4.16 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
CORT vs RPRX Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, RPRX has a market cap of 25.9B. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while RPRX trades at $58.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas RPRX's P/E ratio is 11.13. In terms of profitability, CORT's ROE is +0.08%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CORT is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for CORT.Check RPRX's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
CORT vs WBA Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas WBA's P/E ratio is -1.64. In terms of profitability, CORT's ROE is +0.08%, compared to WBA's ROE of -0.57%. Regarding short-term risk, CORT is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for CORT.Check WBA's competition here
Liquidia Corporation (NASDAQ: LQDA)
CORT vs LQDA Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, LQDA has a market cap of 5.9B. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while LQDA trades at $66.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas LQDA's P/E ratio is 477.71. In terms of profitability, CORT's ROE is +0.08%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, CORT is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for CORT.Check LQDA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
CORT vs KNSA Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, KNSA has a market cap of 5.9B. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while KNSA trades at $77.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas KNSA's P/E ratio is 85.82. In terms of profitability, CORT's ROE is +0.08%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, CORT is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for CORT.Check KNSA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
CORT vs PBH Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, PBH has a market cap of 2.1B. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while PBH trades at $44.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas PBH's P/E ratio is 10.17. In terms of profitability, CORT's ROE is +0.08%, compared to PBH's ROE of +0.09%. Regarding short-term risk, CORT is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for CORT.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
CORT vs HROWL Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas HROWL's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, CORT is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for CORT.Check HROWL's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
CORT vs LTGO Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, LTGO has a market cap of 1.4B. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while LTGO trades at $22.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas LTGO's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to LTGO's ROE of N/A. Regarding short-term risk, CORT is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for CORT.Check LTGO's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
CORT vs HROWM Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas HROWM's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, CORT is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for CORT.Check HROWM's competition here
Cybin Inc. Common Stock (NASDAQ: HELP)
CORT vs HELP Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, HELP has a market cap of 766.7M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while HELP trades at $12.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas HELP's P/E ratio is -2.97. In terms of profitability, CORT's ROE is +0.08%, compared to HELP's ROE of -0.71%. Regarding short-term risk, CORT is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for CORT.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
CORT vs SVA Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas SVA's P/E ratio is -5.68. In terms of profitability, CORT's ROE is +0.08%, compared to SVA's ROE of -0.01%. Regarding short-term risk, CORT is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for CORT.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
CORT vs CUVL Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, CUVL has a market cap of 297.5M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while CUVL trades at $5.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas CUVL's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to CUVL's ROE of N/A. Regarding short-term risk, CORT is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for CORT.Check CUVL's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
CORT vs CELG-RI Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, CELG-RI has a market cap of 242.7M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, CORT is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for CORT.Check CELG-RI's competition here
High Tide Inc. (NASDAQ: HITI)
CORT vs HITI Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, HITI has a market cap of 226.7M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while HITI trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas HITI's P/E ratio is -7.57. In terms of profitability, CORT's ROE is +0.08%, compared to HITI's ROE of -0.36%. Regarding short-term risk, CORT is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for CORT.Check HITI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
CORT vs CTOR Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, CTOR has a market cap of 106M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while CTOR trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas CTOR's P/E ratio is -2.43. In terms of profitability, CORT's ROE is +0.08%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, CORT is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for CORT.Check CTOR's competition here
Atlantic International Corp. (NASDAQ: ATLN)
CORT vs ATLN Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas ATLN's P/E ratio is -0.68. In terms of profitability, CORT's ROE is +0.08%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, CORT is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for CORT.Check ATLN's competition here
Stablecoin Development Corp. (AMEX: SDEV)
CORT vs SDEV Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, SDEV has a market cap of 52.2M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while SDEV trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas SDEV's P/E ratio is -0.18. In terms of profitability, CORT's ROE is +0.08%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, CORT is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for CORT.Check SDEV's competition here
Rite Aid Corporation (NYSE: RAD)
CORT vs RAD Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas RAD's P/E ratio is -0.05. In terms of profitability, CORT's ROE is +0.08%, compared to RAD's ROE of +2.76%. Regarding short-term risk, CORT is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for CORT.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
CORT vs GLTO Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas GLTO's P/E ratio is -1.78. In terms of profitability, CORT's ROE is +0.08%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, CORT is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for CORT.Check GLTO's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
CORT vs NSRX Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, NSRX has a market cap of 29.7M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while NSRX trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas NSRX's P/E ratio is -4.78. In terms of profitability, CORT's ROE is +0.08%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, CORT is more volatile compared to NSRX. This indicates higher risk in terms of short-term price fluctuations for CORT.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
CORT vs SCYX Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, SCYX has a market cap of 28M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while SCYX trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas SCYX's P/E ratio is -1.30. In terms of profitability, CORT's ROE is +0.08%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, CORT is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for CORT.Check SCYX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
CORT vs COSM Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, COSM has a market cap of 17.9M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while COSM trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas COSM's P/E ratio is -0.45. In terms of profitability, CORT's ROE is +0.08%, compared to COSM's ROE of -1.19%. Regarding short-term risk, CORT is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for CORT.Check COSM's competition here
Biofrontera Inc. (NASDAQ: BFRI)
CORT vs BFRI Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, BFRI has a market cap of 16.9M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while BFRI trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas BFRI's P/E ratio is -2.40. In terms of profitability, CORT's ROE is +0.08%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, CORT is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for CORT.Check BFRI's competition here
Cerenome, Inc. (NASDAQ: CNSY)
CORT vs CNSY Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, CNSY has a market cap of 14M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while CNSY trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas CNSY's P/E ratio is -0.48. In terms of profitability, CORT's ROE is +0.08%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, CORT is more volatile compared to CNSY. This indicates higher risk in terms of short-term price fluctuations for CORT.Check CNSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
CORT vs SCNX Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, SCNX has a market cap of 12.7M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while SCNX trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas SCNX's P/E ratio is -0.15. In terms of profitability, CORT's ROE is +0.08%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, CORT is more volatile compared to SCNX. This indicates higher risk in terms of short-term price fluctuations for CORT.Check SCNX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
CORT vs BFRIW Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, BFRIW has a market cap of 11.4M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, CORT's ROE is +0.08%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, CORT is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for CORT.Check BFRIW's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
CORT vs CJJD Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas CJJD's P/E ratio is -0.46. In terms of profitability, CORT's ROE is +0.08%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, CORT is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for CORT.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
CORT vs SSY Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas SSY's P/E ratio is -2.86. In terms of profitability, CORT's ROE is +0.08%, compared to SSY's ROE of -0.09%. Regarding short-term risk, CORT is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for CORT.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
CORT vs POM Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, POM has a market cap of 5.4M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while POM trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas POM's P/E ratio is -0.16. In terms of profitability, CORT's ROE is +0.08%, compared to POM's ROE of +0.16%. Regarding short-term risk, CORT is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for CORT.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
CORT vs BGMS Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, BGMS has a market cap of 5.2M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while BGMS trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas BGMS's P/E ratio is -0.26. In terms of profitability, CORT's ROE is +0.08%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, CORT is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for CORT.Check BGMS's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
CORT vs PAVS Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, PAVS has a market cap of 3.5M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while PAVS trades at $4.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas PAVS's P/E ratio is -0.05. In terms of profitability, CORT's ROE is +0.08%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, CORT is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for CORT.Check PAVS's competition here
Eocene Ltd. (NASDAQ: EOCN)
CORT vs EOCN Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, EOCN has a market cap of 3.5M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while EOCN trades at $3.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas EOCN's P/E ratio is -0.24. In terms of profitability, CORT's ROE is +0.08%, compared to EOCN's ROE of N/A. Regarding short-term risk, CORT is more volatile compared to EOCN. This indicates higher risk in terms of short-term price fluctuations for CORT.Check EOCN's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
CORT vs MDVL Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas MDVL's P/E ratio is -0.05. In terms of profitability, CORT's ROE is +0.08%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, CORT is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for CORT.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
CORT vs ATNFW Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas ATNFW's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, CORT is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for CORT.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
CORT vs BGMSP Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, CORT's ROE is +0.08%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, CORT is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for CORT.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
CORT vs AZNH Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas AZNH's P/E ratio is 38.35. In terms of profitability, CORT's ROE is +0.08%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, CORT is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for CORT.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
CORT vs LFLYW Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, CORT's ROE is +0.08%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, CORT is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for CORT.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
CORT vs PRPH Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, PRPH has a market cap of 175.2K. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas PRPH's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, CORT is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for CORT.Check PRPH's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
CORT vs ESRX Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas ESRX's P/E ratio is 10.69. In terms of profitability, CORT's ROE is +0.08%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, CORT is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for CORT.Check ESRX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
CORT vs IPXL Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas IPXL's P/E ratio is -10.11. In terms of profitability, CORT's ROE is +0.08%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, CORT is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for CORT.Check IPXL's competition here
Shire plc (NASDAQ: SHPG)
CORT vs SHPG Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas SHPG's P/E ratio is 11.35. In terms of profitability, CORT's ROE is +0.08%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, CORT is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for CORT.Check SHPG's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
CORT vs OREX Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, OREX has a market cap of 0. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas OREX's P/E ratio is -0.14. In terms of profitability, CORT's ROE is +0.08%, compared to OREX's ROE of -0.54%. Regarding short-term risk, CORT is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for CORT.Check OREX's competition here
POZEN Inc. (NASDAQ: POZN)
CORT vs POZN Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, POZN has a market cap of 0. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas POZN's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to POZN's ROE of +0.61%. Regarding short-term risk, CORT is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for CORT.Check POZN's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
CORT vs CPD Comparison September 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 11.9B. In comparison, CPD has a market cap of 0. Regarding current trading prices, CORT is priced at $110.29 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 315.11, whereas CPD's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to CPD's ROE of N/A. Regarding short-term risk, CORT is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for CORT.Check CPD's competition here